Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 23, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34 th Annual Healthcare Conference on Thursday,
View HTML
Toggle Summary Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 22, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product,
View HTML
Toggle Summary Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 ,
View HTML
Toggle Summary Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
Completion of rolling NDA submission for zuranolone in MDD and PPD on track for December 2022 Presented additional data across pipeline programs at key medical congresses including data on zuranolone as an investigational oral, once-daily, 14-day treatment for MDD and PPD Company appoints Laura
View HTML
Toggle Summary Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 1, 2022-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault , MD, Ph.D. as Chief Medical Officer. In her new role, Dr.
View HTML
Toggle Summary Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 25, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, November 8, 2022 at 8:00 a.m.
View HTML
Toggle Summary Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study
View HTML
Toggle Summary Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 19, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult
View HTML
Toggle Summary Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 2, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday,
View HTML
Toggle Summary Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022 Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD Enrolling multiple Phase 2 studies across neuropsychiatry and neurology
View HTML